Shahzad Ahmad, MD
Critical Care Medicine · Washington, DCNPI 1730110123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Abbott at 38.4% of the total. Reporting peaked in 2023 at $1,009 and has fallen 66.4% since, to $339 in 2025.
Across 72 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$949
- Insmed, Inc.$284
- AstraZeneca$249
- GSK$231
- Inari Medical, Inc.$129
- Mylan Specialty L.p.$87
- plus $539 from 13 others
What the payments were for
- Food & beverage$2,468100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $949 |
| Insmed, Inc. | 9 | $284 |
| AstraZeneca | 14 | $249 |
| GSK | 12 | $231 |
| Inari Medical, Inc. | 1 | $129 |
| Mylan Specialty L.p. | 5 | $87 |
| Penumbra, Inc. | 1 | $63 |
| Amgen | 2 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $55 |
| Bayer | 2 | $51 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Grifols USA, LLC | 2 | $46 |
| Boehringer Ingelheim | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Vifor Pharma, Inc. | 1 | $30 |
| Gilead | 1 | $24 |
| Alfasigma USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,468 in reported general payments places this provider in the 80th percentile of 59 critical care medicine providers in District of Columbia.
See all critical care medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $22,640 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,919 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $1,816 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,299 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $694 |
| Fluticasone Propionate | 11 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $231 | $27,55934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 59 critical care medicine providers in District of Columbia.
Other critical care medicine in Washington
- Lakhmir ChawlaWashington$441K
- Jonathan ChowWashington$285K
- Tunay KuruWashington$81K
- Vivek JainWashington$14K
- Kellen MulhernWashington$10K
- Jacob CollenWashington$8K
- Danielle DavisonWashington$5K
- Andrew HillWashington$5K
- Dina KianouryWashington$5K
- Brian LeeWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.